Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab for Patients With HER-2/NEU Over-Expressing Metastatic Breast Cancer

NCT00520975 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00520975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00520975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab With or Without Bevacizumab for Patients With HER-2/NEU Over-Expressing Metastatic Breast Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Terminated
Start date
November 30, 2007
Completion date
October 31, 2015
Enrollment
96 (actual)
Sites
373

Conditions

As the registry lists them; a condition with its own page is linked.

breast carcinoma, recurrent breast carcinoma, stage iv breast cancer